Jovičić J, Volaš L, Brkić T, Terzić B, Garić A, Gvozdić B, et al. Opstacles in neuropathic pain treatment in the developing country: Neuropathic pain treatment. Vol. 40, Serbian Journal of Anesthesia and Intensive Therapy. 2018. p. 103–7.
2.
Todorovic-Djilas L, Icin T, Novakovic-Paro J, Bajkin I. Autoimmune thyroid disease and other non-endocrine autoimmune diseases. Vol. 64, Medical review. 2011. p. 183–7.
3.
Palibrk I, Veličković J. Anesthesia in patients with neurological diseases: Coma (neurological disorders and anesthesia). Vol. 40, Serbian Journal of Anesthesia and Intensive Therapy. 2018. p. 45–53.
4.
Ivanović J, Pekmezović T, Drulović J. Interferon beta: Medication which started the revolution in the treatment of multiple sclerosis. Vol. 70, Medicinski podmladak. 2019. p. 53–7.
5.
Suknjaja V. Povezanost vremena nastanka multiple skleroze sa karakteristikama kliničke slike, toka bolesti, nalazima nuklearne magnetne rezonance i likvora. In 2016.
6.
Kamińska J, Koper OM, Piechal K, Kemona H. Multiple sclerosis - etiology and diagnostic potential. Vol. 71, Postępy Higieny i Medycyny Doświadczalnej. 2017. p. 0–0.
7.
Đorđević G, Stamenović J. DEMYELINATION OF THE CENTRAL AND PERIPHERAL NERVOUS SYSTEM: A CASE REPORT. Vol. 56, Acta medica Medianae. 2017. p. 39–43.
8.
Stankov S, Stepančev B. Vitamin D role in multiple sclerosis etiology and therapy. Vol. 52, Medicinski casopis. 2018. p. 15–21.
9.
Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Vol. 9, The Lancet Neurology. 2010. p. 1182–99.
10.
Kostić. Analiza kliničkog toka i progresije multiple skleroze: rezultati studije petogodišnjeg praćenja bolesnika u Srbiji. In 2013.
11.
Republička stručna komisija za izradu i implementaciju vodiča dobre kliničke prakse. Nacionalni vodič dobre kliničke prakse za dijagnostikovanje i lečenje multiple skleroze. Vol. 19. 2013.
12.
Stepanovic-Petrovic R, Micov A. Novel approaches in the treatment of multiple sclerosis. Vol. 65, Arhiv za farmaciju. 2015. p. 223–36.
13.
Simsek H, Zorlu E, Bakal O, Akarsu S, Güney S. Continuous intrathecal baclofen delivery in severely disabling spasticity. Vol. 75, Vojnosanitetski pregled. 2018. p. 1076–82.
14.
Peric P, Antic B, Dincic E, Obradovic D, Arsic S. Treatment of severe spacticity in multiple sclerosis by continuous intrathecal baclofen. Vol. 63, Vojnosanitetski pregled. 2006. p. 187–91.
15.
Villines Z. How does Dawson’s finger relate to multiple sclerosis?
16.
Veinovic G, Stojic-Vukanic Z, Antic-Stankovic J. Lyme borreliosis: Epidemiology, clinical manifestations and treatment. Vol. 65, Arhiv za farmaciju. 2015. p. 129–46.
17.
MSD priručnik dijagnostike i terapije. Sistemski lupus eritematodes. 2014.
18.
Barišić N, Ivanović V, Lehman I, Grđan P. Paediatria Croatica. Vol. 57, Paediatria Croatica. 2013. p. 338–43.
19.
MSD priručnik dijagnostike i terapije. Sjögrenov sindrom. 2014.
20.
Martinović-Kaliterna D, Perković D, Marasović-Krstulović D. Polimiozitis, dermatomiozitis: sindromi preklapanja s autoimunim i malignim bolestima. Vol. 59. 2012. p. 51–2.
21.
Anić B, Cerovec M. Polimiozitis / Dermatomiozitis -klinička slika i terapija. Vol. 59. 2012. p. 44–50.
22.
Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Vol. 51, Muscle & Nerve. 2015. p. 638–56.
23.
Gao S, Luo H, Zhang H, Zuo X, Wang L, Zhu H. Using multi-omics methods to understand dermatomyositis/polymyositis. Vol. 16, Autoimmunity Reviews. 2017. p. 1044–8.
24.
Anaya JM, Corena R, Castiblanco J, Rojas-Villarraga A, Shoenfeld Y. The kaleidoscope of autoimmunity: multiple autoimmune syndromes and familial autoimmunity. Vol. 3, Expert Review of Clinical Immunology. 2007. p. 623–35.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.